These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16022077)

  • 21. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onset of efficacy of tolterodine extended release in patients with overactive bladder.
    Sussman DO; Kraus SR; Carlsson M; Guan Z
    Curr Med Res Opin; 2007 Apr; 23(4):777-81. PubMed ID: 17407634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
    Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
    Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ; Khullar V; Wang JT; Guan Z
    BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolterodine for the treatment of overactive bladder: a review.
    Rovner ES
    Expert Opin Pharmacother; 2005 Apr; 6(4):653-66. PubMed ID: 15934891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolterodine immediate release improves sexual function in women with overactive bladder.
    Hajebrahimi S; Azaripour A; Sadeghi-Bazargani H
    J Sex Med; 2008 Dec; 5(12):2880-5. PubMed ID: 18785896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.
    Homma Y; Kawabe K
    World J Urol; 2004 Oct; 22(4):251-6. PubMed ID: 15455256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT).
    Siami P; Seidman LS; Lama D
    Clin Ther; 2002 Apr; 24(4):616-28. PubMed ID: 12017406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients.
    Michel MC; Oelke M; Goepel M; Beck E; Burkart M
    Neurourol Urodyn; 2007; 26(2):190-5. PubMed ID: 17096320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of mirabegron in overactive bladder: a systematic review and meta-analysis.
    Wu T; Duan X; Cao CX; Peng CD; Bu SY; Wang KJ
    Urol Int; 2014; 93(3):326-37. PubMed ID: 25115445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of the urgency perception scale.
    Cardozo L; Coyne KS; Versi E
    BJU Int; 2005 Mar; 95(4):591-6. PubMed ID: 15705086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder.
    Michel MC; de la Rosette JJ; Piro M; Schneider T
    Eur Urol; 2005 Jul; 48(1):110-5. PubMed ID: 15967259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.
    Herschorn S; Heesakkers J; Castro-Diaz D; Wang JT; Brodsky M; Guan Z;
    Curr Med Res Opin; 2008 Dec; 24(12):3513-21. PubMed ID: 19032133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
    Zinner NR; Mattiasson A; Stanton SL
    J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
    BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolterodine: a safe and effective treatment for older patients with overactive bladder.
    Malone-Lee JG; Walsh JB; Maugourd MF
    J Am Geriatr Soc; 2001 Jun; 49(6):700-5. PubMed ID: 11454106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.